ReviewNature reviews. Immunology2026
Comparative insights into the apoptosome, inflammasomes and PIDDosome.
Review in Nature reviews. Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosomes in inflammatory tissue injury: key pathogenic factors and promising therapeutic agents.Frontiers in immunology · 2026Review
- Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH).Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caspase activation platforms such as the apoptosome, inflammasome and PIDDosome are central to cellular responses to stress, coordinating inflammation, cell death and cell differentiation. Although each of these complexes has been extensively studied in isolation, a comparative understanding of their structural and functional principles is lacking. Here we provide an integrated review of the architecture, activation mechanisms and signalling outputs of these supramolecular signalling platforms. All three of these platforms share a broadly conserved domain architecture and promote proximity-induced caspase activation, but they differ in their subcellular localization and upstream triggers. Furthermore, we explore differences in their downstream effectors and roles in immune signalling, cell cycle regulation and tissue homeostasis. Germline mutations in humans affecting these complexes are linked to cancer predisposition, immune dysregulation and neurodevelopmental disorders, respectively. Finally, we discuss therapeutic opportunities and unresolved questions, aiming to stimulate cross-disciplinary research and translational applications.
Indexed as
Identifiers
42092049What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.